U.S. flag An official website of the United States government

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. GliSODin Skin Nutrients - 552094 - 09/11/2018
  1. Warning Letters

CLOSEOUT LETTER

GliSODin Skin Nutrients MARCS-CMS 552094 —

Recipient:
GliSODin Skin Nutrients

United States

Issuing Office:

United States

 

   

Black HHS-Blue FDA Logo

 

 
 
5001 Campus Drive
College Park, MD 20740

September 11, 2018

Corina Crysler, Co-Founder
GliSODin Skin Nutrients
503-639 Queen St. W.
Toronto, Ontario M5V 2B7
Canada

Dear Ms. Crysler:

The Food and Drug Administration (FDA) has completed an evaluation of your firm's corrective actions in response to our Warning Letter #552094, issued May 18, 2018. Based on our evaluation, it appears you have addressed the violations contained in the Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.
 

Sincerely,
/S/

Carrie Lawlor
Branch Chief
Dietary Supplement and Labeling Assessment Branch
Division of Enforcement
Office of Compliance
Center for Food Safety and Applied Nutrition 

 
Back to Top